Louis Moore Bacon's XENE Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 140,000 shares of Xenon Pharmaceuticals Inc. (XENE) worth $6.27 M, representing 0.09% of the portfolio. First purchased in 2018-Q3, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in XENE, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 143,392 shares. Largest reduction occurred in Q1 2023, reducing 95,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Xenon Pharmaceuticals (XENE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xenon Pharmaceuticals (XENE) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +50,000 | Add 55.56% | 140,000 | $40.15 |
| Q2 2025 | +35,000 | Add 63.64% | 90,000 | $31.30 |
| Q1 2024 | -10,000 | Reduce 15.38% | 55,000 | $43.05 |
| Q4 2023 | +65,000 | New Buy | 65,000 | $46.06 |
| Q2 2023 | -34,417 | Sold Out | 0 | $0.00 |
| Q1 2023 | -95,000 | Reduce 73.41% | 34,417 | $35.79 |
| Q4 2022 | +26,440 | Add 25.68% | 129,417 | $39.43 |
| Q3 2022 | -69,094 | Reduce 40.15% | 102,977 | $36.10 |
| Q2 2022 | +143,392 | Add 499.99% | 172,071 | $30.42 |
| Q1 2022 | +28,679 | New Buy | 28,679 | $30.58 |
| Q1 2020 | -50,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +35,000 | Add 233.33% | 50,000 | $6.32 |
| Q3 2018 | +15,000 | New Buy | 15,000 | $13.20 |
Louis Moore Bacon's Xenon Pharmaceuticals Investment FAQs
Louis Moore Bacon first purchased Xenon Pharmaceuticals Inc. (XENE) in Q3 2018, acquiring 15,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Xenon Pharmaceuticals Inc. (XENE) for 22 quarters since Q3 2018.
Louis Moore Bacon's largest addition to Xenon Pharmaceuticals Inc. (XENE) was in Q2 2022, adding 172,071 shares worth $5.23 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 140,000 shares of Xenon Pharmaceuticals Inc. (XENE), valued at approximately $6.27 M.
As of the Q4 2025 filing, Xenon Pharmaceuticals Inc. (XENE) represents approximately 0.09% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Xenon Pharmaceuticals Inc. (XENE) was 172,071 shares, as reported at the end of Q2 2022.